α-Difluoromethylornithine ototoxicity: Chemoprevention clinical trial results

Archives of Otolaryngology - Head and Neck Surgery

Volumn 123, Issue 12, 1997, Pages 1281-1286

  Pasic, Thomas R ^a,c   Heisey, Dennis ^b   Love, Richard R ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; PLACEBO;

ADULT; ARTICLE; AUDITORY THRESHOLD; BLADDER CANCER; CANCER PREVENTION; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

EID: 0031454230     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1997.01900120031004     Document Type: Article

References (18)

1. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol. 1982; 243:212-221.
2. Russell DH. Ornithine decarboxylase: a key regulatoiy enzyme in normal and neoplastic growth. Drug Metab. 1985;16:1-88.
3. Williams K, Romano C, Dichter MA, Molinoff PB. Modulation of the NMDA receptor by polyamines. Life Sci. 1991;48:469-498.
4. Love RR, Carbone PP, Verma AK, et al. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst. 1993; 85:732-737.
5. Abeloff MD, Lavik M, Luk GD, et al. Phase I trial and pharmocokinetic studies of alpha-difluoromethylornitnine. J Clin Oncol. 1984;2:124-130.
6. Lipton A, Harvey HA, Glenn J, et al. A phase I study of hepatic arterial infusion using difluoromethylornithine. Cancer. 1989;63:433-437.
7. Splinter TAW, Romihn JC. Phase I study of alpha-difluoromethylornithine and methyl-GAG. Eur J Cancer Clin Oncol. 1986;22:61-67.
8. Maddox AM, Keating MJ, McCreadie KE, Estey E, Freireich EJ. Phase I evaluation of intravenous difluoromethylornithine - a polyamine inhibitor. Invest New Drugs. 1985;3:287-292.
9. Abeloff MD, Rosen ST, Luk GD, Baylin SB, Zeltzman M, Sjoerdsma A. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat Rep. 1986;70:843-845.
10. Meyskens FL, Kingley EM, Glattke T, Loescher L, Booth A. A phase II study of alpha-difluoromethylornithine for the treatment of metastatic melanoma. Invest New Drugs. 1986;4:257-262.
11. Croghan MK, Aickin MG, Meyskens FL. Dose-related alpha- difluoromethylornithine ototoxicity. Am J Clin Oncol. 1991;14:331-335.
12. Levine VA, Prados MD, Alfred YungW KH, Gleason MJ, Ictech S, Malec M. Treatment of recurrent gliomas with efiornithine. J Natl Cancer Inst. 1992;84:1432-1437.
13. Salzer TA, Coker NJ, Henley CM. Localization of ornithine decarboxylase in the developing inner ear of the rat. Presented at the meeting of the Association for Research in Otolaryngology; St Petersburg Beach, Fla; February 7, 1994. Page 107. ARO abstracts.
14. Zajic G, Henley C. DFMO impairs cochlear anatomical development in the rat. Presented at the meeting of the Association for Research in Otolaryngology; St Petersburg Beach, Fla; February 7, 1994. Page 109. ARO abstracts.
15. Davis K, Buentello R, DelRosaria M, Jung R, Henley C. DFMO inhibits cochlear polyamine metabolism in the developing pigmented rat. Presented at the meeting of the Association for Research in Otolaryngology; St Petersburg Beach, Fla; February B, 1993. Page 24. ARO abstracts.
16. Schweitzer L, Bell JM, Stotkin TA. Impaired morphological development of the dorsal cochlear nucleus in hamsters treated postnatally with difluoromethylornithine. Neuroscience. 1987;23:1123-1132.
17. Cornelius J, Mattox DE, Miller KD, Brownell WE. An animal model of hearing loss from α-difluoromethylomithine. Arch Otolaryngol Head Neck Surg. 1989;115:1234-1237.
18. Ficker E, Taglialatela M, Wible BA, Henley CM, Brown AM. Spermine and sperinidine as gating molecules for inward rectifier potassium channels. Science. 1994; 266:1068-1072.